Critical Outcome Technologies Inc. Announces Pilot Project Conclusion

* Reuters is not responsible for the content in this press release.

Mon Aug 17, 2009 4:19pm EDT 

  LONDON, ONTARIO, Aug 17 (MARKET WIRE) -- 
Critical Outcome Technologies Inc. (COTI) (TSX VENTURE: COT) announced
today that COTI has received notification from Merck KGaA (FRANKFURT:
MRK) of Darmstadt, Germany that it decided to discontinue the pursuit of
compounds under the pilot project announced on October 17, 2007. The
project called for COTI to identify drug discovery candidates for a
specific oncology cellular target of importance to Merck KGaA.

    About Critical Outcome Technologies Inc. (COTI)

    COTI is formed around a unique computational platform technology called
CHEMSAS(R), which allows for the accelerated identification, profiling
and optimization of targeted small molecules potentially effective in the
treatment of human diseases for which current therapy is either lacking
or ineffective. Currently, six targeted libraries of lead compounds are
under active development: small cell lung cancer, HIV integrase
inhibitors, acute adult leukemia, multiple sclerosis, colorectal cancer
and alzheimer's disease.

    For further information, please visit the website at
www.criticaloutcome.com.


 
 Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the policies of
the TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.

Contacts:
Critical Outcome Technologies Inc.
Michael Barr
Director of Business Development and Marketing
519-858-5157
mbarr@criticaloutcome.com

Critical Outcome Technologies Inc.
Michael Cloutier
Chief Executive Officer
519-858-5157
mcloutier@criticaloutcome.com
www.criticaloutcome.com

Copyright 2009, Market Wire, All rights reserved.

-0-
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.